Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Open accessAbstract
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CATIE is an early precursor to the SMART in chronic schizophrenia.
“An example of an early precursor to the SMART is the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) [54] in chronic schizophrenia.”
From Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) · cites this paper as [54]
In schizophrenia, since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists introduced 50 years ago.
“In schizophrenia, for example, recent studies have shown that since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists, which were introduced 50 years ago (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
While effective in reducing positive symptoms, pharmacological therapy left cognitive dysfunctions and negative symptoms unchanged in the large majority of patients with schizophrenia.
“While effective in reducing the positive symptoms, the cognitive dysfunctions and negative symptoms, two major determinants for outcome and level of functioning, remained unchanged in the large majority of patients.”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Over the last 50 years, pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress.
“Over the last 50 years, the pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793 · see citing works
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829 · see citing works
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724 · see citing works
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428 · see citing works
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,060 · see citing works
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,035 · see citing works
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works
Self-citationLeucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795 · see citing works
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 729 · see citing works
Keefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 690 · see citing works
Self-citationStroup, T., Mcevoy, J., Swartz, M., Byerly, M., Glick, I., Cañive, J., McGee, M., Simpson, G., Stevens, M., & Lieberman, J. (2003) · Schizophrenia bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 647 · see citing works
Self-citationChakos, M., Lieberman, J. A., Hoffman, E. B., Bradford, D. W., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 632 · see citing works
Self-citationCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · see citing works
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C. U., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 518 · see citing works
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 359 · see citing works
Wahlbeck, K., Cheine, M. V., Essali, A., & Adams, C. E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 355 · see citing works
Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E. C., Caroff, S., et al. (2003) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.290.20.2693 · Cited by 319 · see citing works
Self-citationGlucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P. C., Evins, A. E., Hayden, D. L., Weber, M., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 317 · see citing works
Tollefson, G. D., & Sanger, T. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 306 · see citing works
Depressive Signs and Symptoms in Schizophrenia
Tollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.250 · Cited by 261 · see citing works
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L. S., Kreyenbuhl, J. A., Revicki, D. A., & Buchanan, R. W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.11.1021 · Cited by 235 · see citing works
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167 · see citing works
Keefe, R. S. E., Mohs, R. C., Bilder, R. M., Harvey, P. D., Green, M. F., Meltzer, H. Y., Gold, J. M., & Sano, M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006990 · Cited by 110 · see citing works
Self-citationSwartz, M. S., Perkins, D. O., Stroup, T. S., McEvoy, J. P., Nieri, J., & Haak, D. C. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006989 · Cited by 107 · see citing works
Self-citationTuunainen, A., Wahlbeck, K., & Gilbody, S. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00212-2 · Cited by 104 · see citing works
Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence
Citrome, L., & Volavka, J. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216279 · Cited by 90 · see citing works
Rosenheck, R. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.1.85 · Cited by 54 · see citing works
Self-citationDavis, S. M., Koch, G. G., DAVIS, C. E., & LaVange, L. M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006993 · Cited by 44 · see citing works
Self-citationRosenheck, R. A., Doyle, J., LESLIE, D. L., et al. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006994 · Cited by 19 · see citing works
Self-citationApproaches to Multisite Clinical Trials: The National Institute of Mental Health Perspective
Lebowitz, B. D., Vitiello, B., & NORQUIST, G. S. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006992 · Cited by 14 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:Suppl:1-56.
Cited by
Sorted by citations
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577 · see citing works
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Visscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.029 · Cited by 2,425 · see citing works
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065 · see citing works
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31135-3 · Cited by 1,753 · see citing works
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · see citing works
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · see citing works
A Meta-Analysis of Cognitive Remediation in Schizophrenia
McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., & Mueser, K. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060906 · Cited by 1,214 · see citing works
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · see citing works
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · see citing works
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Maust, D. T., Kim, H. M., Seyfried, L. S., Chiang, C., Kavanagh, J., Schneider, L. S., & Kales, H. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3018 · Cited by 617 · see citing works
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Foussias, G., & Remington, G. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn094 · Cited by 594 · see citing works
Early intervention in psychosis: concepts, evidence and future directions
MCGORRY, P. D., KILLACKEY, E., & YUNG, A. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00182.x · Cited by 581 · see citing works
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572 · see citing works
Self-citationIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565 · see citing works
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567 · see citing works
Realistic expectations of prepulse inhibition in translational models for schizophrenia research
Swerdlow, N. R., Weber, M., Qu, Y., Light, G. A., & Braff, D. L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1072-4 · Cited by 529 · see citing works
Uhlhaas, P. J., & Singer, W. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.004 · Cited by 512 · see citing works
Early intervention for psychosis
Marshall, M., & Rathbone, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004718.pub3 · Cited by 531 · see citing works
A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Daumit, G. L., Dickerson, F. B., Wang, N.-Y., Dalcin, A., Jerome, G. J., Anderson, C. A. M., Young, D. R., Frick, K. D., Yu, A., Gennusa, J. V., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214530 · Cited by 523 · see citing works
Wamsley, E. J., Tucker, M. A., Shinn, A. K., Ono, K. E., McKinley, S. K., Ely, A. V., Goff, D. C., Stickgold, R., & Manoach, D. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.08.008 · Cited by 492 · see citing works
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489 · see citing works
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490 · see citing works
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Almirall, D., Nahum-Shani, I., Sherwood, N. E., & Murphy, S. A. (2014) · Translational Behavioral Medicine · doi:10.1007/s13142-014-0265-0 · Cited by 453 · see citing works
Insel, T. R. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.540 · Cited by 459 · see citing works
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433 · see citing works
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399 · see citing works
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384 · see citing works
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378 · see citing works
Xia (2009) · doi:10.1192/pb.bp.108.021949 · Cited by 381 · see citing works
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377 · see citing works
Self-citationWu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366 · see citing works
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349 · see citing works
Gitlin, L. N., Winter, L., Burke, J., Chernett, N., Dennis, M. P., & Hauck, W. W. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000300629.35408.94 · Cited by 362 · see citing works
DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-20 · Cited by 333 · see citing works
Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia
Raglio, A., Bellelli, G., Traficante, D., Gianotti, M., Ubezio, M. C., Villani, D., & Trabucchi, M. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181630b6f · Cited by 333 · see citing works
Sowing the seeds of doubt: a narrative review on metacognitive training in schizophrenia
Moritz, S., Andreou, C., Schneider, B. C., Wittekind, C. E., Menon, M., Balzan, R. P., & Woodward, T. S. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.04.004 · Cited by 325 · see citing works
Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement
Juszczak, E., Altman, D. G., Hopewell, S., & Schulz, K. (2019) · JAMA · doi:10.1001/jama.2019.3087 · Cited by 324 · see citing works
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315 · see citing works
Collaborative care for bipolar disorder, Part II: impact on clinical outcome, function, and costs.
Bauer, M. S., McBride, L., Williford, W. O., Glick, H., Kinosian, B., Altshuler, L., Beresford, T., Kilbourne, A. M., & Sajatovic, M. (2006) · Psychiatric Services · doi:10.1176/ps.2006.57.7.937 · Cited by 312 · see citing works
Fribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.055 · Cited by 311 · see citing works
Medication Adherence: A Review of the Literature and Implications for Clinical Practice
Julius, R. J., Novitsky, M. A., & Dubin, W. R. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344917.43780.77 · Cited by 301 · see citing works
Garety, P. A., Fowler, D. G., Freeman, D., Bebbington, P., Dunn, G., & Kuipers, E. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.043570 · Cited by 296 · see citing works
Dropout From Outpatient Mental Health Care in the United States
Olfson, M., Mojtabai, R., Sampson, N. A., Hwang, I., Druss, B., Wang, P. S., Wells, K. B., Pincus, H. A., & Kessler, R. C. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.7.898 · Cited by 303 · see citing works
Lenze, E. J., Mulsant, B. H., Blumberger, D. M., Karp, J. F., Newcomer, J. W., Anderson, S. J., Dew, M. A., Butters, M. A., Stack, J. A., Begley, A. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00308-6 · Cited by 283 · see citing works
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works
Ballard, C., Corbett, A., Orrell, M., Williams, G., Moniz-Cook, E., Romeo, R., Woods, B., Garrod, L., Testad, I., Woodward-Carlton, B., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002500 · Cited by 263 · see citing works
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262 · see citing works
Kales, H. C., Valenstein, M., Kim, H. M., McCarthy, J. F., Ganoczy, D., Cunningham, F., & Blow, F. C. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101710 · Cited by 258 · see citing works
Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257 · see citing works
Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., & Lieberman, J. A. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn067 · Cited by 258 · see citing works
Self-citationHyman, S. E. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003142 · Cited by 260 · see citing works
What’s in a name? Compliance, adherence and concordance in chronic psychiatric disorders
Chakrabarti, S. (2014) · World Journal of Psychiatry · doi:10.5498/wjp.v4.i2.30 · Cited by 257 · see citing works
INRICH: interval-based enrichment analysis for genome-wide association studies
Lee, P. H., O'Dushlaine, C., Thomas, B., & Purcell, S. M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts191 · Cited by 238 · see citing works
Dose-dependent expression of claudin-5 is a modifying factor in schizophrenia
Greene, C., Kealy, J., Humphries, M. M., Gong, Y., Hou, J., Hudson, N., Cassidy, L. M., Martiniano, R., Shashi, V, Hooper, S. R., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.156 · Cited by 235 · see citing works
Uhlhaas, P. J., & Singer, W. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.019 · Cited by 243 · see citing works
Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G., & Ellingrod, V. L. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1890 · Cited by 235 · see citing works
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234 · see citing works
Schlosser, D. A., Campellone, T. R., Truong, B., Etter, K., Vergani, S., Komaiko, K., & Vinogradov, S. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby078 · Cited by 206 · see citing works
Martin, B. C., Wiley-Exley, E. K., Richards, S., Domino, M. E., Carey, T. S., & Sleath, B. L. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1k671 · Cited by 226 · see citing works
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · see citing works
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · see citing works
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223 · see citing works
Self-citationCorrell, C. U., Rubio, J. M., Inczedy-Farkas, G., Birnbaum, M. L., Kane, J. M., & Leucht, S. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0624 · Cited by 214 · see citing works
Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
Huang, J., Perlis, R. H., Lee, P. H., Rush, A. J., Fava, M., Sachs, G. S., Lieberman, J., Hamilton, S. P., Sullivan, P., Sklar, P., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09091335 · Cited by 213 · see citing works
Self-citationSchizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214 · see citing works
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211 · see citing works
Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial
Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18101125 · Cited by 211 · see citing works
Robinson, D. J., Coons, M., Haensel, H., Vallis, M., & Yale, J.-F. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.031 · Cited by 209 · see citing works
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199 · see citing works
Osborn, D. P. J., Hardoon, S., Omar, R. Z., Holt, R. I. G., King, M., Larsen, J., Marston, L., Morris, R. W., Nazareth, I., Walters, K., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2133 · Cited by 200 · see citing works
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse
Morgan, A. P., Crowley, J. J., Nonneman, R. J., Quackenbush, C. R., Miller, C. N., Ryan, A. K., Bogue, M. A., Paredes, S. H., Yourstone, S., Carroll, I. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115225 · Cited by 197 · see citing works
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188 · see citing works
Review: Mortality in schizophrenia: a measurable clinical endpoint
Bushe, C. J., Taylor, M., & Haukka, J. (2010) · Journal of Psychopharmacology · doi:10.1177/1359786810382468 · Cited by 185 · see citing works
Association of DNA methylation differences with schizophrenia in an Epigenome-Wide association study
Montano, C., Taub, M. A., Jaffe, A., Briem, E., Feinberg, J. I., Trygvadottir, R., Idrizi, A., Runarsson, A., Berndsen, B., Gur, R. C., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0144 · Cited by 180 · see citing works
Dissecting psychiatric spectrum disorders by generative embedding
Brodersen, K. H., Deserno, L., Schlagenhauf, F., Lin, Z., Penny, W. D., Buhmann, J. M., & Stephan, K. E. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.11.002 · Cited by 173 · see citing works
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182 · see citing works
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180 · see citing works
Elman, I., Borsook, D., & Lukas, S. E. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301051 · Cited by 169 · see citing works
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · see citing works
Functional magnetic resonance imaging of impaired sensory prediction in schizophrenia
Shergill, S. S., White, T. P., Joyce, D. W., Bays, P. M., Wolpert, D. M., & Frith, C. D. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2974 · Cited by 163 · see citing works
Medication Adherence in Schizophrenia: Exploring Patients', Carers' and Professionals' Views
Kikkert, M. J., Schene, A. H., Koeter, M. W. J., Robson, D., Born, A., Helm, H., Nose, M., Goss, C., Thornicroft, G., & Gray, R. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl011 · Cited by 164 · see citing works
Factors That Affect Adherence to Bipolar Disorder Treatments: A Stated-Preference Approach
Johnson, F. R., Özdemir, S., Manjunath, R., Hauber, A. B., Burch, S. P., & Thompson, T. R. (2007) · Medical Care · doi:10.1097/mlr.0b013e318040ad90 · Cited by 164 · see citing works
Schizophrenia and physical health problems
Von Hausswolff‐Juhlin, Y., Bjartveit, M., Lindström, E., & Jones, P. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01309.x · Cited by 161 · see citing works
Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., Gleason, T. C., Vertrees, J. E., Weingart, K., Tal, I., et al. (2017) · JAMA · doi:10.1001/jama.2017.8036 · Cited by 159 · see citing works
Chen, E. Y. H., Hui, C. L. M., Lam, M. M. L., Chiu, C. P. Y., Law, C. W., Chung, D. W. S., Tso, S., Pang, E. P. F., Chan, K. T., Wong, Y. C., et al. (2010) · BMJ · doi:10.1136/bmj.c4024 · Cited by 151 · see citing works
Treatment with antipsychotics and the risk of diabetes in clinical practice
Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.076935 · Cited by 152 · see citing works
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151 · see citing works
McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., Ray, N., Lamberti, J. S., Buckley, P. F., Wilkins, T. M., et al. (2014) · JAMA · doi:10.1001/jama.2014.4310 · Cited by 151 · see citing works
Self-citationJansen, J. E., Gleeson, J., Bendall, S., Rice, S., & Alvarez-Jimenez, M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.016 · Cited by 144 · see citing works
Management of Neuropsychiatric Symptoms in People with Dementia
Ballard, C., & Corbett, A. (2010) · CNS Drugs · doi:10.2165/11319240-000000000-00000 · Cited by 147 · see citing works
Jarskog, L. F., Hamer, R. M., Catellier, D. J., Stewart, D. D., LaVange, L., Ray, N., Golden, L. H., Lieberman, J. A., Stroup, T. S., & for the METS Investigators (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12010127 · Cited by 145 · see citing works
Self-citationParikh, S. V., Zaretsky, A., Beaulieu, S., Yatham, L. N., Young, L. T., Patelis-Siotis, I., MacQueen, G. M., Levitt, A., Arenovich, T., Cervantes, P., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07343 · Cited by 145 · see citing works
Current electroconvulsive therapy practice and research in the geriatric population
Kerner, N., & Prudic, J. (2014) · Neuropsychiatry · doi:10.2217/npy.14.3 · Cited by 146 · see citing works
- Authors
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
- Affiliations
- New York State Psychiatric Institute (US)
- Duke University (US)
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1209-1223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159155203
- Cited by
- 5,892
- References
- 32
- Citations by year
- 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
- FWCI
- 258.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Case Western Reserve University
- Foundation of Hope for Research and Treatment of Mental Illness
- Otsuka Pharmaceutical
- National Institutes of Health (n01mh90001-21-0-0)
- University of North Carolina at Chapel Hill
- National Institute of Mental Health (N01 MH90001, MH90001)
- Janssen Pharmaceuticals
- School of Medicine, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
